Moreover, patients with other biliary diseases such as benign biliary tumors, cholecystitis, choledocholithiasis, and cholangitis have clinical presentation, blood chemistry of liver function test and tumor markers of carbohydrate antigen 19–9 (CA19–9) and carcinoembryonic antigen (CEA), and imaging feature of biliary obstruction similarly to CCA, which make it difficult to distinguish CCA from other biliary diseases [6–8]. Here, CEACAM5 is linked to choledocholithiasis.